SCHEMBL16626498

SCHEMBL16626498

CNCc1cn(S(=O)(=O)c2cccc(OC(F)(F)F)c2)c2cc(Nc3ccc(OC)cc3F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 3/20 0.43
HTR6 P50406 14/20 0.42
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
DRD2 P14416 2/20 0.36
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
HTR1E P28566 1/20 0.36
HTR1F P30939 1/20 0.36
HTR7 P34969 1/20 0.36
DRD3 P35462 1/20 0.36
ADRB2 P07550 1/20 0.36
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16626473 0.94 HTR6 (0.46) HTR6DRD2HTR1AHTR1DHTR1B
Hydrochloric Acid SCHEMBL16619180 0.94 HTR6 (0.45) HTR6DRD2HTR1AHTR1DHTR1B
SCHEMBL17971562 0.92 FBP1 (0.43) FBP1HTR6PPARGPPARDPPARA
SCHEMBL17971564 0.92 FBP1 (0.43) FBP1HTR6PPARGPPARDPPARA
SCHEMBL16626491 0.92 FBP1 (0.43) FBP1HTR6PPARGPPARDPPARA
Hydrochloric Acid SCHEMBL16618832 0.92 FBP1 (0.42) FBP1HTR6PPARGPPARDPPARA
SCHEMBL16626492 0.92 FBP1 (0.47) FBP1HTR6PPARGPPARDPPARA
SCHEMBL17971563 0.92 FBP1 (0.47) FBP1HTR6PPARGPPARDPPARA
Hydrochloric Acid SCHEMBL16618843 0.91 FBP1 (0.47) FBP1HTR6PPARGPPARDPPARA
SCHEMBL16626511 0.91 HTR6 (0.42) FBP1HTR6RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI FBP1 74/4885HTR6 166/4885PPARG 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.